AMLN is trading at 2.7X 2011 est. sales of $1.07 Bil. Giant problem ridden GENZ with negative sales growth will be taken out at about 5X sales. Here are the specific FY+1 Price/Sales of comparable takeovers of pure recombinant biotechs
DNA by Roche 7.6X 27% prem
MEDI by Astra Zeneca 10.6X 70% prem
MLNM by Takeda 15.6X 86% prem
IMCL by BMY 9X 73% prem
OSIP by Astellas 8.1X 68% prem
MOGN by Eisai 9.5X 37% prem
PHRM by CELG 10.8X 53% prem
ABII by CELG no sales 60% prem
MYOG by GILD no sales 50% prem
MEDX by BMY no sales 93% prem
CGRB by JNJ no sales 19% prem
FACT by ABT 10X 75% prem
SIRT by GSK no sales 91% prem
IDEV by ENDP 6.6X 232% prem
No comments:
Post a Comment